On October 10, SenzaGen participated in the Vator Securities Unicorn Summit, a capital market day organized to bring together some of the most innovative and fast-growing Swedish life science companies with investors. Anki Malmborg Hager presented Senzagen’s developments and accelerated efforts towards further strengthening the commercial organization and the global presence of GARD®, a group of tests for animal-free safety testing. […]
About Tina Dackemark Lawesson
This author has not written his bio yet.
But we are proud to say that Tina Dackemark Lawesson contributed 59 entries already.
Entries by Tina Dackemark Lawesson
On October 15, SenzaGen’s CEO Anki Malmborg Hager was interviewed by Swedish financial media EFN about SenzaGen’s cruelty-free test platform GARD®, our business model and new sales targets. The result was a short and to-the-point interview about our core business and our future. You will find the filmed interview (in Swedish) here: https://www.efn.se/bors-finans/senzagen-ersatter-djurforsok-kemikalietester/
David W Roberts, Liverpool John Moores University, Liverpool Introduction – Non-Animal Prediction: the 21st Century Consensus Because of the biological complexity of the skin sensitisation process no single in chemico or in vitro assay will be an appropriate replacement for an animal-based assay such as LLNA or GPMT… …to ensure a mechanistic basis and cover the […]
SenzaGen will participate in the Vator Securities Unicorn Summit, which takes place today, October 10, at Medicon Village in Lund. Anki Malmborg Hager will present Senzagen´s developments and accelerated efforts towards further strengthening the commercial organization and the global presence of SenzaGen’s platform GARD®, a group of tests for animal-free safety testing. Unicorn Summit is a capital market day organized by Vator Securities to bring together some […]
Regulatory Toxicology and Pharmacology, Volume 98, October 2018, Pages 155-160, https://doi.org/10.1016/j.yrtph.2018.07.014. David W.Roberts Highlights Prediction of skin sensitization potential does not need multiple assays representing Key Events of the AOP. This has been argued on theoretical grounds and is now tested against published data. A single assay, GARD™, can outperform combinations of OECD test guideline […]
SenzaGen will attend the 7th Medicon Valley Inhalation Symposium – Future Opportunities of Inhalation 2018, 3- 4 October at Medicon Village. A two-day symposium on New drugs, Inhalation devices, Dissolutions, Tox and Pre-Clinical testing and Regulatory updates. Dr Henrik Johansson will hold a presentation on Thursday, October 4 at 09:25, on the topic “Predictive Respiratory […]
Don’t miss the interesting article in Chemical Risk Manager in Chemical Watch, written by Dr. Emma Davies, with the title; Skin sensitization integrated testing strategies need rethink, expert suggests. Emma Davies is interviewing the UK academic Dr. David Roberts after his publication of an article in Regulatory Toxicology and Pharmacology in July where he is discussing […]
Inspelning från telefonkonferens (19 september, 2018) gällande ECVAMs utvärdering av GARDskin flyttad till extra möte i den vetenskapliga kommittén under våren 2019, på svenska. Recording from telephone conference (September 19, 2018) regarding ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019, in Swedish. Nedan finner du även transkript från telefonkonferensen, […]
SenzaGen’s CEO Anki Malmborg Hager is invited to participate and to speak at EIC Innovators’ Summit in Berlin on September 10, 2018. Anki has been selected to share her inspiring story and success as a female entrepreneur to raise awareness of Europe’s economic power of women investors and entrepreneurs. Don’t miss the workshop “Women entrepreneurs […]